CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

Abstract

This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors. Phase: PHASE2 Status: RECRUITING Conditions: High-risk R/R LBCL Interventions: Axicabtagene Ciloleucel

Keywords

Sources